Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2HC
|
|||
| Former ID |
DIB016207
|
|||
| Drug Name |
GSK-2302032A
|
|||
| Synonyms |
PRAME ASCI (NSCLC), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (non-small cell lung cancer), GlaxoSmithKline
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01149343) Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.